Brazil tests lung cancer screening in smokers
NCT ID NCT07279948
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 3 times
Summary
This study will screen 477 current or former smokers in Brazil for lung cancer using CT scans. It aims to see how often the scans give false alarms (false positives) in a region where lung infections are common. The goal is to improve screening accuracy and reduce unnecessary follow-up procedures.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could show how to effectively screen for lung cancer in regions with high rates of granulomatous disease, reducing unnecessary procedures.
- What could go wrong
- This is an early-stage implementation study, not testing a new treatment. Results may not apply to other populations, and false positives could still cause anxiety or extra tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 477 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The population of this study will be adult patients, both sexes, a high-risk smoker selected from a population with a high prevalence of granulomatous disease. The smokers at high risk for developing lung cancer, in a population with a high prevalence of granulomatous disease made up of SUS users registered in the Smoking Cessation Program in the Municipality of Rio de Janeiro, Brazil.
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: In order, to be eligible for the study, patients must fulfill all the following inclusion criteria: * Age between ≥50 and ≤80 years. * Be a current smoker or have quit 15 years ago or less. * Have participated or are currently participating in smoking cessation program. * Lifetime smoking exposure equal to or greater than 20 pack-year. * Provided signed informed consent (ICF) Exclusion Criteria: * In order, to be exclude for the study, patients must at least one of the following exclusion criteria: * Contraindications to the screening examination: (claustrophobic or weighing more than 130 kgs). * Inability to climb 3 stair steps non-stop (36 steps). * Disabling dyspnea * Symptomatic (with signs and symptoms suspicious of breast cancer lung, namely): * pleuritic chest pain * rapidly progressive dyspnea of recent onset * hemoptysis * unexplained hoarseness, lasting more than 1 month. * bone pain * supraclavicular lymphadenopathy or cervical lymphadenopathy persistent * unexplained weight loss of 5% or more of weight in less than 6 months * Previous history of malignant neoplasm (excluding non-melanoma skin cancer) diagnosed less than 10 years before the date of the interview; * Patients with diagnostic of severe psychiatric disease * Immunosuppressed by illness or drugs. * Subjected to anterior lung resection even when determined due to an etiology other than malignant neoplasia. * Person with a serious terminal illness that contraindicates curative lung surgery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Research Site
Rio de Janeiro, 20230-130, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?
- Amazon plant put to the test against Cancer's relentless tiredness
- Can a virtual stress program help working spouses care for cancer patients without burning out?
- Freezing probe aims to kill lung tumors through the airways